Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily DosingBOSTON and EDISON, New Jersey - – Pharmacokinetic Analysis of Atrial Fibrillation Study May Explain Bleeding Rate Difference between Once-Daily and Twice-Daily Dosing Regimens with Same Total Exposure of Factor Xa Inhibitor – Osteoporosis Drug Heritage Continues Ahead of 10th AnniversaryLONDON - Study Results Demonstrate Patients Continue to Adhere to Treatment With Raloxifene To view a Vodcast of Professor Peyman Hadji presenting the data click here: 62.193.238.61/blueprinttv/expert/Expert-Opinion.html EVISTA(R) Improves Patient Compliance in Osteoporosis ManagementLONDON - Study Results Demonstrate Patients Adhere to Treatment Regimens With EVISTA(R) To view a Vodcast of Professor Peyman Hadji presenting the data click the following link: 62.193.238.61/blueprinttv/expert/Expert-Opinion.html |